ABCL - AbCellera Biologics Inc.
Pre-market:
| Previous close | 6.83 |
| Open | 6.82 |
| Bid | 6.95 x 4000 |
| Ask | 6.99 x 1100 |
| Day's range | 6.68 - 6.95 |
| 52-week range | 5.53 - 14.97 |
| Volume | |
| Avg. volume | 2,092,585 |
| Market cap | 1.995B |
| Beta (5Y monthly) | -0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.67 |
Business WireAbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
VANCOUVER, British Columbia, May 29, 2023--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
Simply Wall St.Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss
It's nice to see the AbCellera Biologics Inc. ( NASDAQ:ABCL ) share price up 16% in a week. But that is minimal...
Business WireAbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
VANCOUVER, British Columbia, May 24, 2023--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to invest CA$401 million in the project, and the Governments of Canada and British Columbia will contrib
- Simply Wall St.
AbCellera Biologics First Quarter 2023 Earnings: EPS Misses Expectations
AbCellera Biologics ( NASDAQ:ABCL ) First Quarter 2023 Results Key Financial Results Revenue: US$12.2m (down 96% from...
Motley FoolAbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q1 2023 Earnings CallMay 04, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to AbCellera first-quarter 2023 business update conference call.
ZacksAbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
VANCOUVER, British Columbia, April 17, 2023--AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
Motley Fool1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
Artificial intelligence (AI) is hotter than ever thanks in large part to the intense interest sparked by OpenAI's ChatGPT. Interestingly, though, total private investment in AI decreased by nearly 27% in 2022, according to Stanford University's latest AI Index Report. The healthcare sector should provide a huge opportunity for investors in the years to come.
Business WireAbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
VANCOUVER, British Columbia, April 11, 2023--AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
Business WireAbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
VANCOUVER, British Columbia, April 06, 2023--AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
Business WireAbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
VANCOUVER, British Columbia & LONDON, March 22, 2023--AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
Business WireAbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
VANCOUVER, British Columbia, March 14, 2023--AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
- Simply Wall St.
Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 9.9% drop adds to a year losses
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable...
Business WireAbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
VANCOUVER, British Columbia, February 23, 2023--AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
- Motley Fool
AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript
Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q4 2022 Earnings CallFeb 21, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon.
ZacksAbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireAbCellera Reports Full Year 2022 Business Results
VANCOUVER, British Columbia, February 21, 2023--AbCellera Reports Full Year 2022 Business Results
Business WireAbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
VANCOUVER, British Columbia, February 01, 2023--AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
Business WireAbCellera to Report Full Year 2022 Financial Results on February 21, 2023
VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
ZacksIs the Options Market Predicting a Spike in AbCellera (ABCL) Stock?
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
Business WireAbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
VANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
- Simply Wall St.
Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ZacksStrength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Simply Wall St.
AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at AbCellera Biologics' (NASDAQ:ABCL) recent performance, when its stock has...